Ayahuasca and anxiolytics: contraindications and precautions

Key points at a glance

• Anti-anxiety medicines are not a single family: benzodiazepines, Z-drugs, buspirone, pregabalin, gabapentin, hydroxyzine and beta-blockers do not share the same mechanisms.
• The main risk is not always serotonergic. It often involves sedation, memory, breathing, coordination, rebound anxiety and psychological stability.
• Abruptly stopping benzodiazepines can be dangerous. Health authorities recommend a gradual, individualised reduction when stopping is necessary.
• Someone who depends on an anti-anxiety medicine to sleep, avoid a panic attack or manage daily life may not be at the right point for an ayahuasca retreat.
• Every anti-anxiety medicine must be disclosed, even if taken "only in the evening", "only in a crisis" or "at a low dose".

1. Why anti-anxiety medicines need a different approach

When discussing antidepressants and ayahuasca, the central issue is often the serotonergic interaction with the MAO inhibitors present in the vine. With anti-anxiety medicines, the subject is broader. Many of these treatments affect neuronal inhibition, excitability, sleep, alertness or the body's stress responses. They can change how a person enters the experience, remembers it, breathes, vomits, gets up, asks for help or moves through fear.

The question is therefore not: "does this medicine block ayahuasca?" The question is: "what does this medicine tell us about the person's current state, and what could it change in the safety of the ceremony?" Someone who has occasionally taken an anti-anxiety medicine for years in a stable context is not in the same situation as someone just prescribed one after a panic crisis, a breakup, severe insomnia or a traumatic episode.

A responsible centre must avoid two extremes. The first is to trivialise all anti-anxiety medicines because they are not all SSRIs. The second is to automatically treat them as a uniform prohibition. Good practice is an individual assessment, with strong caution around benzodiazepines, sleeping tablets, combinations with alcohol/opioids and anxiety symptoms that are not stabilised.

2. The main families to know

3. Benzodiazepines: the most sensitive point

Benzodiazepines are effective at rapidly reducing anxiety, supporting sleep, relaxing the body or preventing certain seizures. They can also create physical dependence. The FDA has strengthened warnings for this class because of the risks of abuse, misuse, dependence and withdrawal. It also notes that no single tapering schedule suits everyone: reduction must be gradual and individualised.

At an ayahuasca retreat, benzodiazepines raise several questions. If the person takes them in the evening to sleep, what happens on ceremony nights? If they take them in a crisis, what happens if intense fear arises during the session? If they stop before coming, are they experiencing rebound anxiety or withdrawal? If they continue, are they too sedated to participate fully and stay coordinated?

A team may sometimes think of a benzodiazepine as simply a "rescue medicine". This shortcut is dangerous. Yes, some medical teams use benzodiazepines in specific circumstances to manage agitation. But that does not mean a person who is dependent or has recently withdrawn is automatically suited to a retreat. A ceremonial setting is not a medical unit, and the aim is not to compensate for instability with sedatives.

4. Rebound anxiety and insomnia: two signs to take seriously

Rebound anxiety is anxiety returning more severely after reducing or stopping a treatment. It can appear as inner agitation, hypervigilance, panic attacks, chest tightness, fear of dying, obsessive thoughts or inability to sleep. In a retreat context, these signs can be amplified by travel, a change of location, the group, the diet and anticipation of the ceremony.

Insomnia matters just as much. Someone who arrives exhausted, has slept three hours a night for a week, or stopped their sleeping medicine too quickly enters the experience with an already vulnerable nervous system. Ayahuasca nights are long. Recovery is part of safety. Major sleep deprivation can increase confusion, emotional reactivity and the risk of a difficult experience.

For facilitators, a simple rule helps: the state in which the person arrives matters as much as the treatment they have taken. Someone in withdrawal or an anxiety crisis is not simply "very ready to work". They may be too activated to benefit from an intense setting.

5. Sedation, vomiting and physical safety

Ayahuasca frequently causes nausea, vomiting, diarrhoea, temperature changes, fatigue and the need to stand up or lie down. A sedative medicine can alter alertness, coordination and the ability to ask for help. It can also make it harder to distinguish normal fatigue, confusion, dissociation, a medicine's effect or an unusual reaction.

The risk is not merely theoretical. During a ceremony, people move in the dark, sometimes go to the toilet, bend over to vomit, lie back down and go through emotional waves. Excessive sedation increases the risk of falls, poor coordination or more complex monitoring. It can also prevent the person from integrating what happens, or cause amnesia that makes the aftermath more confusing.

Combinations are particularly important: alcohol, opioids, sleeping tablets, sedating antihistamines, pregabalin, gabapentin, certain antidepressants and benzodiazepines can add to one another's effects on the central nervous system. A person must therefore disclose every product, not just those they call "anti-anxiety medicines".

6. Buspirone, pregabalin, hydroxyzine: do not oversimplify

Buspirone

Buspirone is sometimes seen as "milder" because it does not work like a benzodiazepine and does not cause the same type of dependence. Yet it acts on serotonergic receptors. In an ayahuasca context, it must therefore be disclosed and assessed, especially when combined with an antidepressant.

Pregabalin and gabapentin

These medicines are prescribed for anxiety in some countries or for neuropathic pain. They can cause drowsiness, dizziness and coordination problems. They can also be difficult for some people to stop. The issue is not just direct interaction with ayahuasca, but overall safety and nervous system stability.

Hydroxyzine

Hydroxyzine is an antihistamine also used for anxiety. It can cause sedation and dryness, alter attention and sometimes raise cardiac concerns depending on the person's background. It therefore sits at the overlap between anti-anxiety medicines and antihistamines and must not be forgotten in the questionnaire.

7. The real indicator: current emotional autonomy

An anti-anxiety medicine is not just a molecule. It tells us something about how a person regulates their nervous system. Some people take one occasionally in very rare situations. Others cannot sleep, travel, speak in a group or stay alone without their medicine. These two realities are not equivalent.

Before an ayahuasca retreat, current emotional autonomy must therefore be assessed. Can the person move through rising anxiety without endangering themselves? Can they ask for help? Can they remain connected with the team? Have they experienced panic attacks with a fear of dying? Do they have non-drug strategies that work? Can they delay an impulsive response?

These questions are not there to judge. They help avoid putting someone into an intensity they cannot process. Ayahuasca can open deep fears. If the person currently needs an anti-anxiety medicine to contain everyday fear, the priority may be to strengthen a more stable therapeutic framework first.

8. Before, during and after: three different moments

Before the retreat

The greatest risk before the retreat is improvisation: rapid discontinuation, unsupervised reduction, a hidden last dose, a bad night's sleep, stressful travel or drinking alcohol to calm anxiety. The centre must look at the preceding days and weeks, not just the ceremony night.

During the ceremony

During the ceremony, the team must know whether someone has recently taken an anti-anxiety medicine or sleeping tablet. This changes what needs observing: consciousness level, memory, coordination, breathing, ability to vomit safely, need for accompaniment to the toilet, risk of confusion or disinhibition. An anxious person may ask to take their medicine in the middle of the night. This situation must have been anticipated, not decided in a panic.

After the retreat

After the retreat, some people feel calmer and want to reduce their treatment; others experience heightened sensitivity and need stability. In both cases, the medical decision remains with the prescriber. The integration team can help put the experience into words, but must not advise medication changes.

9. Combinations to check systematically

Anti-anxiety medicines become more sensitive when combined with other products. The questionnaire must therefore ask broadly, because participants do not always think to disclose everything.

• Alcohol: even moderate consumption can add to sedation and disrupt sleep.
• Opioids and strong painkillers: a particularly sensitive combination with benzodiazepines and gabapentinoids.
• Sedating antihistamines: hydroxyzine, diphenhydramine, doxylamine or promethazine can increase drowsiness and confusion.
• Antidepressants: many people take anti-anxiety medicines and antidepressants together; the assessment must then combine both articles.
• Cannabis: sometimes used to calm anxiety, it can also increase dissociation, panic or confusion in some people.
• Supplements: valerian, kava, St John's wort, 5-HTP, melatonin or sedating plants must be mentioned.

The practical aim is not to create an endless list, but to obtain an honest picture of the person's nervous system. The more products there are, the more the team needs to slow down.

10. What the participant must disclose

Useful disclosure must be specific. Saying "I take an anti-anxiety medicine from time to time" is not enough. The centre needs to know:

• the exact active ingredient and brand name;
• the dose, frequency, time of administration and date of the last dose;
• whether the medicine is taken every day, occasionally or in an emergency;
• the reason for prescription: generalised anxiety, panic, sleep, trauma, pain, withdrawal or another reason;
• how long it has been taken and any attempts to stop;
• symptoms if the person misses a dose;
• other treatments, alcohol, cannabis, opioids, antihistamines, antidepressants and supplements;
• the current state: sleep, recent crises, dark thoughts and daily stability.

11. What a responsible centre must do

12. Questions to ask the centre

• Do you ask about anti-anxiety medicines and sleeping tablets in the medical questionnaire?
• Do you distinguish between benzodiazepines, buspirone, hydroxyzine, pregabalin and sleeping medicines?
• What do you do if someone is in withdrawal or sleeping very poorly before the retreat?
• Do you prohibit alcohol, drugs and undisclosed sedatives before the ceremony?
• Can you postpone someone who is too unstable even if they are determined to come?
• What monitoring is provided during the night if someone is anxious or sedated?
• What integration do you offer if the experience reactivates anxiety after the retreat?

13. For facilitators: when to say no or not now

A centre may want to welcome an anxious person, especially if they express a sincere intention. But intention is not enough. Here are situations where the cautious response is often postponement:

• a recent panic attack involving an emergency department visit or fear of dying;
• a recent increase in anti-anxiety medicine doses;
• ongoing discontinuation or reduction of a benzodiazepine;
• severe insomnia in the days before the retreat;
• using alcohol or cannabis to compensate for anxiety;
• inability to attend without a rescue medicine whose use has not been agreed;
• significant dissociation, acute trauma or a major relationship crisis;
• refusal to share necessary medical information.

Postponement can be expressed gently: "we hear your motivation, but your nervous system seems too unstable at the moment; we would rather wait for a stronger foundation". This protects better than heroic encouragement to "push through the fear".

14. Preparation without stopping treatment

When a retreat is postponed, the participant can still move forward. They can strengthen therapeutic support, work with breathing, stabilise sleep times, reduce stimulants, learn to recognise early signs of a crisis, build a support plan with someone close and clarify the exact function of their treatment with their doctor.

This preparatory work is not a consolation prize. It is often what later allows someone to approach a ceremony more safely. A retreat should not be used to force a capacity for regulation that the person does not yet have. It should build on resources already present.

15. Quick checklist for participant and centre

Anti-anxiety medicines require a shared, documented decision. Here is a simple checklist to reduce blind spots:

• The person knows the exact active ingredient, dose, frequency and last dose.
• They can explain why the medicine was prescribed and what happens if they miss a dose.
• They are not changing their treatment solely to be accepted on a retreat.
• They are sleeping enough in the preceding days.
• They are not compensating for anxiety with alcohol, cannabis or undisclosed sedatives.
• The team knows whether there is a rescue medicine and under what circumstances it is normally used.
• Any possible adjustment remains medically supervised beforehand and is never decided simply to allow attendance at the retreat.
• The centre has a clear right to postpone if the current anxiety makes the setting too intense.

This checklist is deliberately practical. Problems rarely arise because a technical word is missing from the questionnaire; they arise because a concrete detail was not shared: "I took it last night", "I can no longer sleep without it", "I increased it a week ago", "I panic if I do not have it in my bag".

16. FAQ

Sources and references

• ICEERS - Ayahuasca Safety Profile
• Drug-drug interactions involving classic psychedelics: a systematic review
• FDA - Boxed Warning on benzodiazepines
• MedlinePlus - Serotonin syndrome